Anti-CD26 monoclonal antibodies as therapy for diseases...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07658923

ABSTRACT:
Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.

REFERENCES:
patent: 5120642 (1992-06-01), Schlossman et al.
patent: 6218372 (2001-04-01), Nabel et al.
patent: 6573096 (2003-06-01), Chen
patent: 6951924 (2005-10-01), Rosen et al.
patent: 2004-500116 (2004-01-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 02/04610 (2002-01-01), None
patent: WO 02/31134 (2002-04-01), None
Skin Cancer Foundation's definition of melanoma downloaded on Jan. 5, 2009.
Aldinucci et al., “In vitro and in vivo effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies,”British Journal of Haematology, 110:188-196, 2000.
Asada et al., “Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma,”Histopathol., 23:265-270, 1993.
Bauvois et al., “Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia,”Br. J. Cancer, 79:1042-1048, 1999.
Carbone et al., “CD26/dipeptidyl peptidase IV expression in human lymphomas is restricted to DC30-positive anaplastic large cell and a subset of T-cell non-Hodgkin's lymphomas,”Human Pathol., 25:1360-1365, 1994.
Carbone et al., “The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias,”Blood, 86(12):4617-4626, 1995.
Dang et al.,“1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation,”J. Immunol., 147:2825-2832, 1991.
Dang et al., “Cell surface modulation of CD26 by aniti-1F7 monoclonal antibody,”J. Immunol., 145:3963-3971, 1990.
Dang et al., “Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways,”J. Immunol., 144:4092-4100, 1990.
Dang et al., “FcR-mediated crosslinking of Tal (CDw26) induces human T lymphocyte activation,”Cell. Immunol., 125:42-57, 1990.
Dang et al., “Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family,”J. Exp. Med., 172:649-652, 1990.
Datto et al., “Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism,”Proc. Natl. Acad. Sci. USA, 92:5545-5549, 1995.
De Meester, et al., “Antibody-binding profile of purified and cell-bound CD26—designation of BT5/9 and TA5.9 to the CD26 cluster,”Immunobiology, 188:145-158, 1993.
Dong et al., “Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response,”J. Immunology, 156:1349-1355, 1996.
Dong et al., “Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function,”Mol. Immunol., 35:13-21, 1998.
El-Deiry et al., “WAF1, a potential mediator of p53 tumor suppression,”Cell, 75:817-825, 1993.
El-Deiry et al., “WAF1/CIP1 is induced in p53-mediated G1arrest and apoptosis,”Cancer Res., 54:1169-1174, 1994.
Fleischer et al., “Molecular associations required for signaling via dipeptidyl peptidase IV (CD26),”Adv. Exp. Med. Biol., 421:117-125, 1997.
Fleischer, “A novel pathway of human T cell activation via a 103 kD T cell activation antigen,”J. Immunol., 138:1346-1350, 1987.
Fox et al., “Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody,”J. Immunol., 133:1250-1256, 1984.
Hegen et al., “Cross-linking of CD26 by antibody induces tyorsine phosphorylation and activation of mitogen-activated protein kinase,”Immunology, 90:257-264, 1997.
Ho et al., “In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma karpas 299,”Clinical Cancer Res., 7:2031-2040, 2001.
Hühn et al., “Molecular analysis of CD26-mediated signal transduction in T cells,”Immunology Letters, 72:127-132, 2000.
Hühn et al., “The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV (CD26) molecule,”Cellular Immunology, 192:33-40, 1999.
Kähne et al., “Early phosphorylation events induced by DPIV/CD26-specific inhibitors,”Cell. Immunol., 189:60-66, 1998.
Kubota et al., “Involvement of dipeptidyl peptidase IV in an in vivo immune response,”Clin. Exp. Immunol., 89:192-197, 1992.
Mattern et al., “Antin-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1phase of the cell cycle,”Immunobiol., 188:36-50, 1993.
Morimoto and Schlossman, “The structure and function of CD26 in the T-cell immune response,”Immunol. Rev., 161:55-70, 1998.
Morimoto et al.,“1F7, a novel cell surface molecule, involved in helper function of CD4 cells,”J. Immunol., 143:3430-3439, 1989.
Morimotoet al., “The isolation and characterization of the human helper inducer T cell subset,”J Immunol., 134: 3762-3769, 1985.
Morrison et al., “A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase,”J. Exp. Med.,177:1135-1143, 1993.
Tanaka et al., “CD26 (Dipeptidyl peptidea IV/DPP IV) as a novel molecular marker for differntiated thyroid carcinoma,”Int. J. Cancer, 64:326-331, 1995.
Tanaka et al., “Cloning and functional expression of the T cell activation antigen CD26,”Journal of Immunology, 149:481-486, 1992.
Tanaka et al., “The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity,”Proc. Natl. Acad. Sci. USA, 90:4586-4590, 1993.
Torimoto et al., “Biochemical characterization of CD26 (dipeptidyl peptidae IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies,”Mol. Immunol., 29:183-192, 1992.
Torimoto et al., “Coassociation of CD26 (Dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes,”J. Immunol., 147:2514-2517, 1991.
Voet et al., In:Biochemistry, John Wiley & Sons, pp. 964, 965, 1074 and 1075, 1990.
von Bonin et al., “Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway,”Immunol Rev., 161:43-53, 1998.
von Bonin et al., “The T-cell receptor associated ξ-chain is required but not sufficient for CD26 (dipeptidylpeptidase IV) mediated signaling,”Immunology Letters, 55:179-182, 1997.
Waga et al., “The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA,”Nature, 369:574-578, 1994.
Wesley et al., “A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells,”J. Exp. Med., 190:311-322, 1999.
Yang and Kornbluth, “All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners,”Trends Cell Biol., 9:207-210, 1999.
Office Action, issued in Japanese Application 2002-589043, dated Jul. 11, 2008 (English Translation).
Gaetaniello et al., “Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells,”Hepatology, 4:934-942, 1998.
Supplemental Search Report, issued in European Application No. 02769684.8-2402, mail date Jul. 3, 2009.
Cheng et al., “Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin,”J. Biol. Chem., 273:24207-24215, 1998.
Gonzalez-Gronow et al., “Interaction of plasminogen with dipeptidyl peptidase IV in

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-CD26 monoclonal antibodies as therapy for diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-CD26 monoclonal antibodies as therapy for diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD26 monoclonal antibodies as therapy for diseases... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4189201

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.